Search results

Skip to results

Area of interest

Type

Status

Last updated

Showing 7606 to 7620 of 8200 results

  1. Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab (TA202)

    This guidance has been withdrawn because Novartis has discontinued ofatumumab (Arzerra). Ofatumumab will continue to be available for people who need it. Contact Clinigen at managedacess@clinigengroup.com or 01932 842100 for details.

    Technology appraisal guidance
    Published
    27 October 2010

  2. Liraglutide for the treatment of type 2 diabetes mellitus (TA203)

    This guidance has been updated and replaced by NICE guideline NG28.

    Technology appraisal guidance
    Last updated
    1 December 2014

  3. Alzheimer's disease (mild to moderate) - donepezil, rivastigmine and galantamine (TA19)

    This guidance has been replaced by NICE technology appraisal guidance 111.

    Technology appraisal guidance
    Published
    23 January 2001

  4. Denosumab for the treatment of therapy-induced bone loss in non-metastatic prostate cancer (terminated appraisal) (TA194)

    This guidance has been updated and replaced by NICE guideline CG175.

    Technology appraisal guidance
    Published
    28 July 2010

  5. Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (TA196)

    This guidance has been replaced by NICE technology appraisal guidance 326.

    Technology appraisal guidance
    Published
    25 August 2010

  6. Tocilizumab for the treatment of rheumatoid arthritis (TA198)

    This guidance has been updated and replaced by NICE technology appraisal guidance 247.

    Technology appraisal guidance
    Published
    25 August 2010

  7. Certolizumab pegol for the treatment of rheumatoid arthritis (TA186)

    This guidance has been updated and replaced by NICE technology appraisal guidance 375.

    Technology appraisal guidance
    Published
    24 February 2010

  8. Laparoscopic surgery for colorectal cancer (TA17)

    This guidance has been replaced by NICE technology appraisal guidance 105. 

    Technology appraisal guidance
    Published
    16 December 2000

  9. Cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck (TA172)

    This guidance has been updated and replaced by NICE technology appraisal guidance 473.

    Technology appraisal guidance
    Published
    24 June 2009

  10. Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (TA205)

    This guidance has been updated and replaced by NICE technology appraisal guidance 293.

    Technology appraisal guidance
    Published
    27 October 2010

  11. Diabetes (type 2) - pioglitazone (TA21)

    This guidance has been replaced by NICE technology appraisal guidance 63 [Replaced by NICE guideline CG66].

    Technology appraisal guidance
    Published
    27 March 2001

  12. Sorafenib for the treatment of advanced hepatocellular carcinoma (TA189)

    This guidance has been replaced by NICE technology appraisal guidance 474.

    Technology appraisal guidance
    Published
    26 May 2010

  13. Erlotinib for the treatment of non-small-cell lung cancer (TA162)

    This guidance has been updated and replaced by NICE technology appraisal guidance 374.

    Technology appraisal guidance
    Last updated
    1 December 2012

  14. Febuxostat for the management of hyperuricaemia in people with gout (TA164)

    This guidance has been updated and replaced by NICE guideline NG219.

    Technology appraisal guidance
    Published
    17 December 2008

  15. Cochlear implants for children and adults with severe to profound deafness (TA166)

    This guidance has been updated and replaced by NICE technology appraisal guidance 566.

    Technology appraisal guidance
    Published
    28 January 2009